OTX-TKI, a hydrogel-based implant in development for sustained-release delivery of axitinib, has been well tolerated in patients with neovascular age-related macular degeneration, according to a study.
At the virtual Association for Research in Vision and Ophthalmology meeting, James G. Wong, MBBS, of Strathfield Retina Clinic in Australia, said that unmet needs remain in neovascular AMD treatment.
“Therapeutic challenges associated with current therapies include rapid clearance of VEGF inhibitors requiring repeated injections every 1 to 2 months to maintain effective concentrations,”